IL17A and systemic lupus erythematosus: The inhibition of mTORC1 with rapamycin leads to Treg cell expansion, contraction of IL-17 producing cells and suppression of STAT3 signaling—all of which represent attractive therapeutic targets in people with SLE [43–45].